TY - JOUR
T1 - Urinary transforming growth factor beta-1 as a marker of renal dysfunction in sickle cell disease
AU - Mohtat, Davoud
AU - Thomas, Rosemary
AU - Du, Zangfang
AU - Boakye, Yaa
AU - Moulton, Thomas
AU - Driscoll, Catherine
AU - Woroniecki, Robert
N1 - Funding Information:
This work was supported by NIH training grant to R.T. DK007110-34, and an Emerald Foundation, Inc. grant to R.P.W. We thank Drs. Peter Belamarich and Andrew Racine and the nurses from the Pediatric Outpatient Clinics at The Children’s Hospital at Montefiore for helping with subject recruitment.
PY - 2011/2
Y1 - 2011/2
N2 - Renal dysfunction affects 5-18% of patients with sickle cell disease (SCD). To date, no studies have described urinary levels of transforming growth factor β-1 (TGF-β1), a marker of fibrosis, and neutrophil gelatinase-associated lipocalin (NGAL), a marker of acute/chronic kidney disease, as biomarkers in identifying patients at risk of developing renal disease in SCD. We hypothesized that SCD subjects will have increased urinary excretion of TGF-β1 and NGAL compared with healthy controls (CTR). We examined 51 SCD subjects: 42 HbSS, 8 HbSC, and 1 HbSD. Sixteen out of 42 patients with HbSS were on hydroxyurea (HU). Urinary excretion of TGF-β1 was 26.4∈±∈1.5 pg/mgCr in SCD subjects vs 15. 0∈±∈2.4 pg/mgCr in CTR (p∈<∈0.00001). SCD patients with hemoglobin∈<∈9 g/dl had higher urinary TGF-β1 than patients with milder anemia (p∈=∈0.002). Urinary TGF-β1 trended lower in HbSS patients treated with HU (23.61∈±∈2.6 pg/mgCr), vs patients not on HU (27.69∈±∈1.8 pg/mgCr; p∈=∈0.055). There was no correlation between urinary TGF-β1 and microalbuminuria or estimated glomerular function. There was no difference in urinary NGAL in SCD patients vs CTR. We suggest that urinary TGF-β1 may serve as a marker of early renal injury in SCD.
AB - Renal dysfunction affects 5-18% of patients with sickle cell disease (SCD). To date, no studies have described urinary levels of transforming growth factor β-1 (TGF-β1), a marker of fibrosis, and neutrophil gelatinase-associated lipocalin (NGAL), a marker of acute/chronic kidney disease, as biomarkers in identifying patients at risk of developing renal disease in SCD. We hypothesized that SCD subjects will have increased urinary excretion of TGF-β1 and NGAL compared with healthy controls (CTR). We examined 51 SCD subjects: 42 HbSS, 8 HbSC, and 1 HbSD. Sixteen out of 42 patients with HbSS were on hydroxyurea (HU). Urinary excretion of TGF-β1 was 26.4∈±∈1.5 pg/mgCr in SCD subjects vs 15. 0∈±∈2.4 pg/mgCr in CTR (p∈<∈0.00001). SCD patients with hemoglobin∈<∈9 g/dl had higher urinary TGF-β1 than patients with milder anemia (p∈=∈0.002). Urinary TGF-β1 trended lower in HbSS patients treated with HU (23.61∈±∈2.6 pg/mgCr), vs patients not on HU (27.69∈±∈1.8 pg/mgCr; p∈=∈0.055). There was no correlation between urinary TGF-β1 and microalbuminuria or estimated glomerular function. There was no difference in urinary NGAL in SCD patients vs CTR. We suggest that urinary TGF-β1 may serve as a marker of early renal injury in SCD.
KW - Biomarkers
KW - Fibrosis progression
KW - Sickle cell nephropathy
UR - http://www.scopus.com/inward/record.url?scp=78751591610&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=78751591610&partnerID=8YFLogxK
U2 - 10.1007/s00467-010-1677-9
DO - 10.1007/s00467-010-1677-9
M3 - Article
C2 - 21107986
AN - SCOPUS:78751591610
VL - 26
SP - 275
EP - 280
JO - Pediatric Nephrology
JF - Pediatric Nephrology
SN - 0931-041X
IS - 2
ER -